表紙画像

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

As a new-generation CDK inhibitor, a CDK4/6 inhibitor combined with endocrine therapy has been successful in the treatment of advanced estrogen receptor-positive (ER+) breast cancer. Although there has been overall progress in the treatment of cancer, drug resistance is an emerging cause for breast...

保存先:

書誌詳細
主要な著者:	Zhen Li (著者), Wei Zou (著者), Ji Zhang (著者), Yunjiao Zhang (著者), Qi Xu (著者), Siyuan Li (著者), Ceshi Chen (著者)
フォーマット:	図書
出版事項:	Frontiers Media S.A., 2020-11-01T00:00:00Z.
主題:	article
オンライン･アクセス:	Connect to this object online.
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
著者:: Chao Dong, 等
出版事項: (2021)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
著者:: Amrallah A. Mohammed, 等
出版事項: (2019)

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
著者:: Chen Hu, 等
出版事項: (2023)

Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis
著者:: Zhihao Zhang, 等
出版事項: (2024)

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
著者:: Dongqing Pu, 等
出版事項: (2024)

Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database
著者:: Jinhua Chen, 等
出版事項: (2024)

Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
著者:: Yan-ping Liu, 等
出版事項: (2022)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
著者:: Chao-Yue Sun, 等
出版事項: (2022)

Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis
著者:: Xin Guan, 等
出版事項: (2024)

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
著者:: Ratnakar Reddy Kuchukulla, 等
出版事項: (2022)

Novel CDK4/6 lnhibitor, WXJ-8 -Exerts Anti-effects Through Cell Cycle in Breast Cancer
著者:: Jing Ji, 等
出版事項: (2023)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
著者:: Corona SP, 等
出版事項: (2018)

Temporal changes in cyclinD-CDK4/CDK6 and cyclinE-CDK2 pathways: implications for the mechanism of deficient decidualization in an immune-based mouse model of unexplained recurrent spontaneous abortion
著者:: Zhuo Chang, 等
出版事項: (2022)

Binding selectivity-dependent molecular mechanism of inhibitors towards CDK2 and CDK6 investigated by multiple short molecular dynamics and free energy landscapes
著者:: Lifei Wang, 等
出版事項: (2023)

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
著者:: Rossana Roncato, 等
出版事項: (2022)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
著者:: Nannan Wang, 等
出版事項: (2022)

Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma
著者:: Ying Zhu, 等
出版事項: (2021)

WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6
著者:: Jing Ji, 等
出版事項: (2023)

Clinical use of Abemaciclib a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with breast cancer - literature review
著者:: Katarzyna Maria Krukar, 等
出版事項: (2024)

Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania
著者:: Adina Turcu-Stiolica, 等
出版事項: (2024)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
著者:: Efthymia Skafida, 等
出版事項: (2023)

MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers
著者:: Dorsay Sadeghian, 等
出版事項: (2022)

Unveiling the impact of CDK8 on tumor progression: mechanisms and therapeutic strategies
著者:: Xiaomin Yin, 等
出版事項: (2024)

A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
著者:: Hua Zhang, 等
出版事項: (2023)

Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia
著者:: Zhuoying Chen, 等
出版事項: (2024)

Prognostic significance of malignant pleural effusions in patients with advanced luminal B breast cancer
著者:: You-ming Han, 等
出版事項: (2024)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
著者:: Yi-fan Chen, 等
出版事項: (2011)

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma
著者:: Zhong-Kun Xia, 等
出版事項: (2021)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
著者:: Federico Sottotetti, 等
出版事項: (2022)

A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with "bone-only" metastatic breast cancer
著者:: Ilona Tornyi, 等
出版事項: (2023)

Wogonin Induces Apoptosis and Reverses Sunitinib Resistance of Renal Cell Carcinoma Cells via Inhibiting CDK4-RB Pathway
著者:: Yong Wang, 等
出版事項: (2020)

The Luminous Face
著者:: Wells, Carolyn, 1862-1942

The Luminous Blonde
著者:: Howard, Hayden, 1925-2014; Freas, Kelly, 1922-2005 [Illustrator]

Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
著者:: Fernanda Cardoso da Silva, 等
出版事項: (2023)

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
著者:: Alexander D. James, 等
出版事項: (2020)

Locally Advanced Breast Cancer Patient's Recurrence Rates Comparison Received Steroidal and Nonsteroidal Aromatase Inhibitor Based on Luminal
著者:: Desak Gede Agung Suprabawati, 等
出版事項: (2024)

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow's oncologists
著者:: L. G. Zhukova, 等
出版事項: (2020)

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database
著者:: Rachel Prevost, 等
出版事項: (2023)

Matrine suppresses cell growth of diffuse large B-cell lymphoma via inhibiting CaMKIIγ/c-Myc/CDK6 signaling pathway
著者:: Jianyou Gu, 等
出版事項: (2021)

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
著者:: Vivian Jiang, 等
出版事項: (2024)